Vicki Oliver, APRN
Acute Care · Oklahoma City, OKNPI 1851692958
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 299 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 39.8% of the total. Reporting peaked in 2022 at $1,662 and has fallen 70.2% since, to $496 in 2024.
Across 299 payments — averaging $15.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$498
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$476
- Merck$229
- Regeneron Healthcare Solutions, Inc.$187
- Gilead$182
- plus $1K from 17 others
What the payments were for
- Food & beverage$4,760100%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 122 | $1,902 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $498 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 36 | $476 |
| Merck | 16 | $229 |
| Regeneron Healthcare Solutions, Inc. | 11 | $187 |
| Gilead | 15 | $182 |
| Daiichi Sankyo Inc. | 9 | $182 |
| QOL Medical, LLC | 8 | $143 |
| Ardelyx, Inc. | 7 | $141 |
| Nestle Healthcare Nutrition Inc. | 7 | $122 |
| Ironwood Pharmaceuticals, Inc | 7 | $111 |
| Johnson & Johnson | 7 | $104 |
| Boston Scientific | 3 | $103 |
| Lilly USA, LLC | 4 | $94 |
| Pharmacosmos Therapeutics Inc. | 4 | $73 |
| Braintree Laboratories, Inc. | 5 | $64 |
| Aimmune Therapeutics, Inc. | 2 | $34 |
| Redhill Biopharma Inc. | 2 | $33 |
| AMAG Pharmaceuticals, Inc. | 2 | $31 |
| Celltrion USA Inc. | 1 | $22 |
| Sandoz | 1 | $20 |
| Fresenius Kabi USA, LLC | 1 | $16 |
| Boehringer Ingelheim | 1 | $14 |
How this compares
$4,782 in reported general payments places this provider in the 85th percentile of 266 acute care providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other acute care in Oklahoma City
- Karen GregoryOklahoma City$68K
- Katrina PyleOklahoma City$13K
- Deborah PeterOklahoma City$12K
- Christopher GordonOklahoma City$12K
- Kelli LeekOklahoma City$10K
- Scottie SmithOklahoma City$8K
- Maria BacaOklahoma City$7K
- Janet FundaroOklahoma City$7K
- Silvia Olivares MendozaOklahoma City$6K
- Bonnie RenfroOklahoma City$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.